NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
September 19, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024
August 27, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
August 13, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
Global Gut Microbiota Markets, Insights and Forecasts to 2031 - Key Players Danone, IFF, Ferring, and Nestle Focusing on R&D and Strategic Partnerships
July 12, 2024 05:35 ET
|
Research and Markets
Dublin, July 12, 2024 (GLOBE NEWSWIRE) -- The "Gut Microbiota Market, By Product, By Application, By Disease Type, By End Users, By Distribution Channel: By Region - Market Size, Industry Dynamics,...
Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers
July 01, 2024 07:47 ET
|
Biomerica, Inc.
inFoods® IBS patients can now conveniently self-collect a blood sample using a simple finger-stick methodology in the privacy of their home inFoods® IBS test is the first of its kind to...
Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024
May 13, 2024 08:19 ET
|
Biomerica, Inc.
With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th...
Biomerica provides update on inFoods® IBS expansion
April 15, 2024 07:47 ET
|
Biomerica, Inc.
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in physicians prescribing inFoods more...
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
March 28, 2024 08:19 ET
|
Biomerica, Inc.
Collaborators at the University of Michigan will present new Data on InFoods® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) --...
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
February 21, 2024 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the...
Constipation Treatment Global Market Report 2023: Growth Trajectories, Product Innovations, and Strategic Acquisitions to 2033
February 09, 2024 09:36 ET
|
Research and Markets
Dublin, Feb. 09, 2024 (GLOBE NEWSWIRE) -- The "Constipation Treatment Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The constipation treatment sector is...